Health economic modeling for medical technologies in Europe
Early and comprehensive economic models to determine economic value proposition and inform healthcare decision-makers
Recent news and posts
Technologies awaiting coverage decisions in Norway
Norway has a national system for the introduction of new health technologies within the specialist health service (“New Methods” framework) through either a national or hospital-based health technology assessment. This framework is mandatory for all innovations before being funded.
In May 2025, the evaluation phase within the “New Methods” framework was deemed complete for the following three technologies, with supporting documentation prepared for the Decision Forum:
- Leadless pacemaker (Micra transcatheter pacing system) for the treatment of cardiac arrhythmias has been under evaluation in the “New Methods” framework since 2023. This represents a re-assessment of the technology, which was previously assessed between 2016 and 2018. A rapid HTA report was completed by the Norwegian Medical Products Agency (NOMA) in December 2024;
- Magnetic resonance-guided high-intensity focused ultrasound (MRgFUS, ExAblate Neuro) for the treatment of essential tremor has been evaluated within the “New Methods” framework since 2023. A full HTA report was completed by NOMA in January 2025;
- Electrical Field Therapy (Optune, Tumor Treating Fields), used alone or in combination with drug therapies for selected glioblastoma patient groups based on genome sequencing and biomarkers, has been under evaluation since 2022. A rapid HTA report was completed by NOMA in December 2024.
With HTA recommendations now available, the Decision Forum has to make the coverage decisions regarding these technologies.
See the full details here (leadless pacemaker), here (MRgFUS), and here (Optune).
This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.